Cargando…

Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes

During the last decade, substantial advances have been made in the understanding of the complex molecular, immunological and cellular disturbances involved in the initiation as well as evolution of myelodysplastic syndromes (MDS). In 85% of the mainly frail and older patient population, anemia is pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubasch, Anne Sophie, Platzbecker, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720617/
https://www.ncbi.nlm.nih.gov/pubmed/31394818
http://dx.doi.org/10.3390/ijms20163853